MimiVax, Inc. Alternatives & Competitors

12 companies similar to MimiVax, Inc. — Disrupting Cancer with Immunotherapy

Prescient Therapeutics

A clinical stage oncology company developing personalised medicine approaches to cancer; c...

14 Post-IPO Equity $3.00M

Australia

Biopharma Biotechnology +3

Imvax, Inc.

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-deriv...

24 $253.70M

Philadelphia, United Stat...

Biotechnology Health and Wellness +1

SELLAS Life Sciences Group, Inc.

A late-stage clinical biopharmaceutical company focused on developing novel therapies for...

18 Post-IPO Equity $101.70M

New York, United States

Biopharma Biotechnology

NexImmune, Inc.

NexImmune, Directing T cell function to restore natural immunity

32 Post-IPO Equity $87.44M

Gaithersburg, United Stat...

Biopharma Biotechnology +1

Track all MimiVax, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Lisata Therapeutics, Inc.

Targeted Therapy Delivered

39 Acquired $4.44M

United States

Biotechnology Health and Wellness +1

Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and...

26 Post-IPO Equity $262.60M

Foster City, United State...

Biotechnology Health Care +1

Veana Therapeutics, Inc.

Veana Therapeutics, Inc is a clinical stage biopharma company developing oral mitochondria...

4 Grant $1.82M

Portland, United States

Biotechnology Health Care +2

Heidelberg Pharma Research GmbH

37 Post-IPO Secondary $284.39M

Ladenburg, Germany

Biotechnology Health Care +1

BriaCell Therapeutics Corp.

Developing Novel Therapies to Destroy Cancer

20 Post-IPO Equity $36.20M

Philadelphia, United Stat...

Biotechnology Health Care +2

Arcellx

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

224 Acquired $8.43B

Redwood City, United Stat...

Biopharma Biotechnology +3

BioMimetix

Late-stage company supported by robust clinical results with a Drug Class: Redox-Active M...

10 Seed $2.00M

Greenwood Village, United...

Biotechnology Pharmaceutical

3T Biosciences

3T is an immunotherapy company developing next-generation, transformative therapies for br...

26 Series A $52.00M

South San Francisco, Unit...

Biopharma Biotechnology +1

About MimiVax, Inc.

MimiVax, Inc. is a privately held, clinical-stage biotechnology company founded in 2012 with a vision to disrupt cancer through highly innovative immunotherapies. The company's lead immunotherapeutic vaccine, , has shown promise by completing a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

Business keywords

Immunotherapy, Cancer Treatment, Clinical-stage Company, Immunotherapeutic Vaccines, Targeted Therapies, Survivin-targeting Technology, Glioblastoma, Multiple Myeloma, Neuro-Endocrine Tumors, Pediatric High Grade Glioma, Medulloblastoma, DIPG, Oncology, Pharmaceutical Development

Frequently Asked Questions

Companies similar to MimiVax, Inc. include Prescient Therapeutics, Imvax, Inc., SELLAS Life Sciences Group, Inc., NexImmune, Inc., Lisata Therapeutics, Inc.. They work in Biotechnology and Pharmaceutical and share MimiVax, Inc.'s focus on oncology, cancer treatment and immunotherapy.

Bounce Watch lists 12 companies that share MimiVax, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches MimiVax, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

MimiVax, Inc. Profile Prescient Therapeutics Alternatives Imvax, Inc. Alternatives SELLAS Life Sciences Group, Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at MimiVax, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.